Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238

Clinical Cancer Research

Volumn 6, Issue 2, 2000, Pages 709-717

  Kiaris, Hippokratis ^a   Schally, Andrew V ^a,b   Nagy, Attila ^a   Sun, Baodong ^a   Szepeshazi, Karoly ^a   Halmos, Gabor ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BODY WEIGHT; CELL SURVIVAL; DOXORUBICIN; GLIOBLASTOMA; HUMANS; MALE; MICE; MICE, NUDE; OCTREOTIDE; PYRROLES; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033981859     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hochberg, F., and Pruitt, A. Neoplastic diseases of the central nervous system. In: E. Braunwald, K. J. Isselbacher, R. G. Petersdorf, J. D. Wilson, J. B. Martin, and A. S. Fauci (eds.), Harrison's Principles of Internal Medicine, 11th ed., pp. 1968-1980. New York: McGraw-Hill, 1987.
2. Salcman, M., and Kaplan, R. S. Intracranial tumors in adults. In: A. R. Moosa, M. C. Robson, and S. C. Schimpff (eds.), Comprehensive Textbook of Oncology, pp. 617-629. Baltimore, MD: Williams & Wilkins, 1986.
3. Schally, A. V., and Nagy, A. Chemotherapy targeted to hormone receptors on tumors. Eur. J. Endocrinol., 141: 1-14, 1999.
4. Hilderbrandt, G., Scheidhauer, K., Luyken, C., Schicha, H., Klug, N., Dahmus, P., and Krisch, B. High sensitivity of the in vivo detection of somatostatin receptors by Indium (DTPA-Octreotide) scintigraphy in meningioma patients. Acta Neurochir., 126: 63-71, 1994.
5. Reubi, J. C., Schaer, J. C., Waser, B., and Mengod, G. Somatostatin (SRIH) messenger ribonucleic acid expression in human neuroendocrine and brain tumors using in situ hybridization histochemistry: comparison with SRIH receptor content. J. Clin. Endocrinol. Metab., 76: 642-647, 1993.
6. Dutour, A., Kumar, U., Panetta, R., Ouafik, L. H., Fina, F., Sasi, R., and Patel, Y. C. Expression of somatostatin receptor subtypes in human brain tumors. Int. J. Cancer, 876: 620-627, 1998.
7. 1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med., 20: 716-731, 1993.
8. Reubi, J. C., Kappeler, A., Waser, B., Laissue, J., Hipkin, R. W., and Schonbrunn, A. Immunohistochemical localization of somatostatin receptors sst2A in human tumors. Am. J. Pathol., 153: 233-345, 1998.
9. Nagy, A., Schally, A. V., Halmos, G., Armatis, P., Cai, R. Z., Csernus, V., Kovacs, M., Koppan, M., Szepeshazi, K., and Kahan, Z. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinod-oxorubicin. Proc. Natl. Acad. Sci. USA, 95: 1794-1799, 1998.
10. Nagy, A., Armatis, P., and Schally, A. V. High-yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin. Proc. Natl. Acad. Sci. USA, 93: 2464-2469, 1996.
11. Koppan, M., Nagy, A., Schally, A. V., Arencibia, J. M., Plonowski, A., and Halmos, G. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. Cancer Res., 58: 4132-4137, 1998.
12. Plonowski, A., Schally, A. V., Nagy, A., Sun, B., and Szepeshazi, K. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Cancer Res., 59: 1947-1953, 1999.
13. Kahan, Z., Nagy, A., Schally, A. V., Hebert, F., Sun, B., Groot, K., and Halmos, G. Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancers after administration of targeted cytotoxic analog of somatostatin, AN-238. Int. J. Cancer, 82: 592-598, 1999.
14. Pinski, J., Schally, A. V., Halmos, G., Szepeshazi, K., and Groot, K. Somatostatin analogues and bombesin/gastrin releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. Cancer Res., 54: 5895-5901, 1994.
15. Cai, R. Z., Szoke, B., Lu, R., Fu, D., Redding, T. W., and Schally, A. V. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc. Natl. Acad. Sci. USA, 83: 1896-1900, 1986.
16. Reile, H., Birnbock, H., Bernhardt, G., Spruss, T., and Schonenberger, H. Computerized determination of growth kinetic curves and doubling times from cells in microculture. Anal. Biochem., 187: 262-267, 1990.
17. Szepeshazi, K., Milovanovic, S., Lapis, K., Groot, K., and Schally, A. V. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LHRH, an analog of somatostatin or a combination. Breast Cancer Res. Treat., 21: 181-192, 1992.
18. Munson, P. J., and Rodbard, D. Ligand: a versatile computerized approach for characterization of ligand binding systems. Anal. Biochem., 107: 220-239, 1980.
19. McPherson, G. A. Analysis of radioligand binding experiments: a collection of computer programs for the IBM PC. J. Pharmacol. Methods, 14: 213-228, 1985.
20. Miyazaki, M., Nagy, A., Schally, A. V., Lamharzi, N., Halmos, G., Szepeshazi, K., Groot, K., and Armatis, P. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hrmone-releasing hormone. J. Natl. Cancer Inst., 89: 1803-1809, 1997.
21. Kaliste-Korhonen, E., Tuovinen, K., and Hänninen, O. Interspecies differences in enzymes reacting with organophosphates and their inhibition by paraoxon in vitro. Hum. Exp. Toxicol., 15: 972-978, 1996.
22. Husain, S. R., Behari, N., Kreitman, R. J., Pastan, I., and Puri, R. K. Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy. Cancer Res., 58: 3649-3653, 1998.
23. Im, S-A., Gomez-Manzano, C., Fueyo, J., Liu, T. J., Ke, L. D., Kim, J-S., Lee, H-Y., Steck, P. A., Kyritsis, A. P., and Yung, W. K. A. Antiangiogenesis treatment for gliornas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res., 59: 895-890, 1999.
24. 3-octreotide (DOTATOC): a pilot study in human gliomas. Clin. Cancer Res., J: 1025-1033, 1999.
25. Banks, W. A., Kastin, A. J., Radulovic, S., Conley, F. K., Johnson, D. L., and Schally, A. V. Selective uptake of the somatostatin analog RC-160 across the blood-brain tumor barrier of mice with KHT sarcomas. Anticancer Drugs, 3: 519-523, 1992.
26. Kiaris, H., and Schally, A. V. Apoptosis versus necrosis: which should be the aim of cancer therapy? Proc. Soc. Exp. Biol. Med., 221: 87-88, 1999.